The first bellwether trial concerning controversial anticoagulant Xarelto has begun in the Eastern District of Louisiana. The late-April 2017 trial is one of four bellwether trials scheduled to take place throughout this spring and summer. The cases all similarly allege that the drug’s manufacturer Janssen Pharmaceuticals did not adequately warn patients about the uncontrollable bleeding risks associated with Xarelto and that it withheld certain safety information regarding the lack of a bleeding antidote.
Many plaintiffs in the Xarelto litigation are represented by Grant & Eisenhofer, a plaintiffs’ firm involved in the Bellwether Selection Committee and co-lead of the Law & Briefing Committee. If you or a loved one experienced complications from taking the drug Xarelto, please call us at (888) 984-7988 for a confidential evaluation of your potential claim.